Basal Cell Carcinoma Treatment Market Forecast 2024-2033: Projected CAGR, Key Drivers, And Trends

Overview and Scope

Basal cell carcinoma (BCC) is a form of skin cancer originating from basal cells, which are responsible for generating new skin cells. It often appears as a small, translucent lump but can have varied presentations. Effective treatment strategies for basal cell carcinoma (BCC) involve tumor removal, considering tumor characteristics, location, size, patient preferences and the practicality of follow-up appointments.

Sizing and Forecast

The basal cell carcinoma treatment market size has grown rapidly in recent years. It will grow from $6.69 billion in 2023 to $7.42 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to increasing prevalence of skin cancer, demand for laser therapy, demand for effective and minimally invasive treatments, rising awareness of basal cell carcinoma treatment.

The basal cell carcinoma treatment market size is expected to see strong growth in the next few years. It will grow to $10.77 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to growing focus on quality of life, aging population, growing research and development in immunotherapies, government initiatives. Major trends in the forecast period include advancements in treatment modalities, early detection technologies, advancements in targeted therapies, telemedicine integration.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/basal-cell-carcinoma-treatment-global-market-report

Segmentation & Regional Insights

The basal cell carcinoma treatment market covered in this report is segmented –

1) By Treatment: Surgery; Medication; Other Treatments

2) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

4) By End-User: Hospitals; Specialty Clinics; Other End-Users

North America was the largest region in the basal cell carcinoma treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in basal cell carcinoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12900&type=smp

Major Driver Impacting Market Growth

The rising incidences of skin cancer, including basal cell carcinoma, are expected to propel the growth of the treatment market going forward. Skin cancer is a disease in which abnormal cells grow uncontrollably in the skin, often caused by exposure to ultraviolet (UV) radiation from the sun or tanning beds. An increased need for targeted and specialized treatment choices is created by the increasing prevalence of skin cancer, especially basal cell carcinoma, which encourages the creation and availability of efficient medicines designed to treat this particular type of cancer. For instance, in January 2023, according to the American Cancer Society, Inc., a US-based cancer research organization, approximately 5.4 million basal and squamous cell skin cancer cases were identified annually in the United States, impacting about 3.3 million individuals. Further, basal cell carcinoma accounts for eight out of ten cases. Therefore, the rising incidence of skin cancer, including basal cell carcinoma, will drive the treatment market.

Key Industry Players

Major players in the basal cell carcinoma treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Fresenius Kabi AG, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Incyte Corporation, Ono Pharma UK Ltd., Cipla Inc., Lupin Limited, Mallinckrodt Pharmaceuticals, LEO Pharma A/S, BeiGene Ltd., Taro Pharmaceutical Industries Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Genentech USA Inc., Palvella Therapeutics LLC.

The basal cell carcinoma treatment market report table of contents includes: